Denali Therapeutics announced the U.S. FDA has placed a hold on the Investigational New Drug (IND) application for DNL919, under development for the treatment of Alzheimer’s disease (AD). The FDA indicated they will provide an official clinical hold letter to Denali in approximately 30 days. Denali plans to provide additional updates pending discussion with the FDA. A few days prior to the hold, Denali presented program progress and expected milestones for 2022 during a corporate presentation at the 40th Annual J.P. Morgan Healthcare Conference. During this presentation, the company announced that Takeda exercised its option in December 2021 to co-develop and co-commercialize DNL919 for the treatment of AD and that the IND application for DNL919 had been submitted. Denali had hoped to begin first-in-human clinical trials of DNL919 in the first half of 2022, with human safety and biomarker data available in the second half of 2022.
DNL919 (ATV:TREM2) is an Antibody Transport Vehicle (ATV) designed to activate TREM2 (ATV:TREM2) and improve microglial function. TREM2 is a receptor expressed on microglia, the resident immune cells of the brain. Loss of function TREM2 genetic muta…
Quality journalism costs money to produce. We will be reinvesting the proceeds of these subscriptions into an increasing volume of high quality, independent, unbiased reporting and expert analysis. Our subscription tiers use the ‘honor system’ – please do not abuse it. All tiers of service provide the same level of access to content. We are grateful for all of you, and we hope you reciprocate.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).